Global Blood Coagulation Testing Market Size, Share, Forecast Report, 2020-2027

Blood coagulation or clotting is the process by which blood changes from liquid to gel, thus, forming clots. These clots result in cessation of bleeding. However, the process of coagulation is hindered in the people suffering from liver disease, thrombophilia, and hemophilia. Various blood coagulation testing procedures are used for diagnosing these diseases, which provide the status of the hemostatic functioning of the patient. Haemostatic involves a coordinated series of interactions between platelets and numerous blood clotting proteins. With increasing prevalence of hemostatic diseases, the demand for blood coagulation testing has increased. To analyses the treatment efficiency against hemostatic diseases, the blood clotting testing is required.

The liver plays an important role in the normal functioning of hemostasis, which helps in preventing bleeding and undue activation of coagulation. According to the Centers for Disease Control and Prevention (CDC), in 2015, around 3.9 million adults were diagnosed with liver disease, which is about 1.6% of adult population of the U.S.

According to a study conducted by the Global Burden of Disease Liver Cancer Collaboration, in 2015, around 854,000 new incidents of liver cancer were found and 810,000 deaths occurred owing to liver cancer globally. Furthermore, it is the sixth most common-incident cancer globally and the fourth most common cause of cancer death.

Moreover, advancing technology in blood coagulation testing is adding fuel to the growth of the market. Furthermore, increasing prevalence of liver disease, thrombophilia, and hemophilia also drives the market growth. However, availability of expensive treatment and poor reimbursement policies in the developing regions of the world are some of the factors, which may hamper the market growth during the forecast period.
Segmentations

The global blood coagulation market is segmented on the basis of product, application, test type, and end user.

On the basis of the product, the market is segmented into clinical laboratory, automated testing, and semi-automated testing.

On the basis of application, the market is segmented into congenital bleeding disorders, acquired bleeding disorders, Von Willebrand disease, and hemophilia.

On the basis of test type, the market is segmented into various testing kits and others. Furthermore, testing kits are segmented into prothrombin time (PT), activated clotting time, D dimer, and fibrinogen (FIB).

On the basis of the end user, the market is segmented into academic institutions, hospitals, and diagnostic laboratories.
Key Players

Some of the major players for the global blood coagulation market are F. Hoffmann-La Roche Ltd. (Europe), Alere Inc. (U.S.), Siemens Healthcare Private Limited (Europe), Accriva Diagnostics (U.S.A.), CoaguSense, Inc. (U.S.), HomoSonics LLC. (U.S.), iLine Microsystems. (Europe), Instrumentation Laboratory (U.S.), Sienco, Inc. (U.S.), SenGenix Inc. (U.S.), Bio/Data Corporation (U.S.)